Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical Trial Disclosure: Learning the Landscape and Reading the Roadmap DIA November 13-14, 2007 Hyatt Regency Bonaventure, Weston, Florida.

Published byKellie Morrison Modified over 7 years ago

Similar presentations

Presentation on theme: "Clinical Trial Disclosure: Learning the Landscape and Reading the Roadmap DIA November 13-14, 2007 Hyatt Regency Bonaventure, Weston, Florida."— Presentation transcript:

1 Clinical Trial Disclosure: Learning the Landscape and Reading the Roadmap
DIA November 13-14, 2007 Hyatt Regency Bonaventure, Weston, Florida

2 Collaboration of SIACS
This program was developed as a cooperative effort by the following DIA Special Interest Area Communities: Good Clinical Practices & Quality Assurance: Clinical Trial Disclosure Working Group Clinical Research Regulatory Affairs Medical Writing

3 5 Co-Located DIA Conferences
4 other co-located DIA meetings Publication Writing and Building Partnerships DIA Outsourcing Summit The Future of Project Management Winning Strategies for Achieving a Quality EDC Clinical Trial Process Delegates can attend sessions in any of the five conferences Common plenary session and networking events

4 5 Co-Located DIA Conferences
November 13-14, 2007 Weston, Florida (Fort Lauderdale area) Hyatt Regency Bonaventure Conference Center and Spa Keynote Address: Drug Development as a Business: The Role of Outsourcing Harold Glass, PhD, Professor, Health Policy, University of the Sciences in Philadelphia

5 Clinical Trial Disclosure Working Group Mission
To provide a professional, neutral forum for members to discuss and share operational best practices, and medical, scientific and regulatory information related to registry and results disclosure activities. To publicize the field worldwide; stimulate members to engage in the evaluation of registration and data disclosure issues worldwide; and to encourage dialog on registration and results disclosure processes and issues among regulators, registrars, academic institutions, industry, and other stakeholders. To create, publish, and promote materials on registry and results disclosure issues and topics and provide educational opportunities including webinars and workshops under DIA auspices.

6 Acronyms AAMC: Association of American Medical Colleges
CTR: Clinical Trial Registry FDAMA: Food and Drug Modernization Act FDARA: FDA Revitalization Act FACT Act: Fair Access to Clinical Trials Act ICMJE: International committee of Medical Journal Editors IFPMA: International Federation of Pharmaceutical Manufacturers and Associations IOM: Institute of Medicine NIH: National Institutes of Health PhRMA: Pharmaceutical Research and Manufacturers of America WHO: World Health Organization ICTRP: International Clinical Trials Registry Platform

7 Public Disclosure of Trial Information
Clinical Trial Life Cycle Part 1: Register Protocol Information Part 2: Post Trial Results One year after trial completion: Marketed drugs At trial initiation Publicly accessible web site clinicaltrials.gov Publicly accessible web site clinicalstudyresults.org

8 Clinical Trial Disclosure Landscape
Inputs PhRMA AAMC IFPMA AMA Ottawa Grp Countries FDAMA NIH Congressional Acts ICMJE IOM WHO-ICTRP States Publicly Accessible Web sites Users Systematic Reviewers (Cochrane, Oregon) Health Policy Makers Journal Editors Researchers & Funders Consumer Advocates

9 Current Disclosure Law/Guidance
Registration Law FDAMA 113 (serious, life threatening indications) Best Pharmaceuticals for Children Act (expanded access trials) State of Maine (hypothesis- testing trials) International Law Guidance ICMJE PhRMA IFPMA WHO Results Disclosure Law State of Maine Guidance PhRMA IFPMA

10 Purpose of Trial Disclosure Conference
This conference will provide practical advice from industry practitioners for complying with worldwide regulations for public disclosure of clinical trial information. Individuals delivering this conference work inside the industry, ensuring company compliance with laws, regulations and other requirements governing the public disclosure of clinical trial information.

11 Chairpersons for Trial Disclosure Conference
Barbara Godlew, RN Associate Director, Publication Coordination and Transparency Compliance Exploratory Development Communications Novartis Pharmaceuticals Corporation Pamela Rose, RN, BSN, ASQ-CMQOE Director Clinical Trial Information Registries TAP Pharmaceutical Products Inc.

12 Agenda for Trial Disclosure Conference
Session 1: Clinical Trial Landscape and Lifecycle: The Relationship Between Disclosure and the Trial Publication Plan Session 2: Stakeholder Street Maps: A Worldwide Overview to Clinical Trial Disclosure Session 3: After the Trial is Completed: What, When, Where, and How to Post Trial Results Session 4: Reading and Following the Road Map: Public Registration of Clinical Protocol Information

13 Agenda for Trial Disclosure Conference
Session 5: Herding Cats Through Canyons: Developing a Company Process for Public Disclosure Session 6: Are You Ready? Preparing for Audit of Clinical Trial Disclosures Session 7: “Emeralds of Experience”: Clinical Trial Disclosure Lessons Learned

14 Clinical Trial Landscape and Lifecycle: The Relationship Between Disclosure and the Trial Publication Plan Session Co-Chairs: Barbara Godlew, Novartis Robert Paarlberg, UCB

15 Session Overview Examine some of the aspects clinical teams should consider when writing a study protocol as well as identifying key stakeholders to include in the publication planning process. Gain knowledge of how patients, families and advocates view public disclosure of clinical trial information. Learn how public disclosure of clinical trial information may impact publication planning.

16 Speakers Landscapes and Lifecycles: From the Perspective of the Publication Plan Barbara Godlew Robert Paarlberg From the Editor’s Desk: How Much is Too Much? Paul Ladenson, MD, Editor-in-Chief, The Journal of Clinical Endocrinology & Metabolism The Path Towards Access and Transparency: The Patient’s Point of View Pat Furlong, President, Parent Project Muscular Dystrophy

17 Stakeholder Street Maps: A Worldwide Overview to Clinical Trial Disclosure
Session Co-Chairs: Gerard Lynch, AstraZeneca Michael Rubison, Abbott

18 Clinical Trial Transparency
The primary vehicles used to provide transparency are the Registration and Result Disclosure of Clinical Trials. Leading global databases and portals include: ClinicalTrials.gov ClinicalStudyResults.org IFPMA.org WHO Search Portal (ICTRP)

19 Disclosure Legislation and Public Policy
This session provides a chronological history of Clinical Trial Disclosure, key milestones and issues, including: FDAMA 113 legislation of serious and life-threatening diseases and conditions US Federal and state legislation and International statutes Industry Agreements by IFPMA, PhRMA, EFPIA and JPMA Policies and Guidelines from Journal Editors (ICMJE) WHO Reporting, Disclosure and Registry Standards

20 Speakers Key Milestones and Issues: A Chronological History of Clinical Trial Disclosure Gerard Lynch, Project Leader, Clinical Trials Website, AstraZeneca Michael Rubison, Senior Director, Global Medical Research and Registration, Abbott

21 After the Trial is Completed: What, When, Where, and How to Post Trial Results
Session Co-Chairs: Tracy J Beck, PhD, Global Medical Business Office Consultant, Eli Lilly and Company Milen Vrabevski, MD, CEO, Comac Medical Ltd.

22 Posting Trial Results The biopharmaceutical industry has used clinical trial registries and results databases as one way to increase clinical trial transparency and public trust. Up until recently, the emphasis has been on registering trials at initiation, but now the focus has shifted towards disclosing results. This session will examine external stakeholders who are shaping the landscape of trial disclosure and what potholes to look out for. Attendees will learn what, when, and how to post results summaries, as well as how to avoid risks of off-label promotion when creating the summaries for public disclosure.

23 Speakers Brief Overview of Posting Clinical Trial Results
Pamela Rose, RN, FNP, ASQ-CMQOE, TAP Pharmaceutical Products Inc. What, Where, and How to Post Results Tracy Beck, PhD, Eli Lilly and Company How to Avoid the Risks of Off-Label Promotion in Results Summaries Bob Naidus, JD, Novartis Pharmaceuticals

24 Reading and Following the Road Map: Public Registration of Clinical Protocol Information
Session Co-Chairs: Maureen Strange, Eli Lilly and Company Barbara Godlew, Novartis Pharmaceuticals

25 Presentation 1: Finding and Unfolding the Map: Legislation Surrounding ClinicalTrials.gov
Clarity on Federal Legislation – a compliance compass Industry is NOT alone, NLM has challenges TOO! Presentation 2: YES! You Can Register a Trial to ClinicalTrials.gov Without a Global Positioning System and We’ll Show You How!! A tutorial build of a registration record in the Protocol Registration System (PRS) Your questions answered

26 Speakers Rebecca Williams, PharmD Annice Bergeris
Assistant Director, ClinicalTrials.gov National Library of Medicine Annice Bergeris Information Research Specialist

27 Herding Cats Through Canyons: Developing a Company Process for Public Disclosure
Session Co-Chairs: Margaret M. Cobb, MD, PhD, Johnson & Johnson Patricia Teden, MBA, Independent Consultant

28 Needs and Decisions Business Context
Multiple study registries and results databases; rules are still changing so the business process needs to be flexible High visibility; premium put on accuracy, completeness, consistency and timeliness Needs and Decisions Create corporate standards for clinical trial disclosure (which studies, which registries, partnership studies, etc) Define process that leverages current clinical trial process and company technology. Enable process with technology? Define roles & responsibilities. Centralized vs. decentralized operations. Use of external resources? Define management oversight and quality steps Create and execute implementation plan

29 Speakers Large Pharma Perspective BioPharm Perspective
Margaret M. Cobb, MD, PhD Senior Director, Global Leader, Clinical Registry Johnson and Johnson Medicines and Nutritionals BioPharm Perspective Anthony K. Taylor, Sr. Clinical Operations Coordinator Targanta Therapeutics Corporation Device Company Perspective Lisa Griffin Vincent, PhD, MA Senior Director, Corporate Clinical R & D Medtronic Inc.

30 Are You Ready? Preparing for Audit of Clinical Trial Disclosures
Session Co-Chairs: John C. McKenney, SEC Associates, Inc. Pamela Rose, TAP Pharmaceutical Products Inc.

31 Audit of Clinical Trial Disclosures
It is becoming increasingly important to ensure that your trial registrations and results postings are accurate, complete, and timely The State of Maine regulations and the FDA Revitalization Act bill pending in Congress include penalties for non-compliance Public image and liability concerns are also strong drivers for companies to ensure they are doing it right This session includes an overview of the fundamental components of a clinical trial disclosure (CTD) audit The heart of this session consists of a panel discussion featuring industry professionals who have participated in CTD audits as auditors/auditees

32 Panelists Auditee Perspective
Shawn M. Pelletier, Associate Director R&D Operations Bristol-Myers Squibb Company Valerie V. Phillips, MA, Manager Clinical Trial Disclosure Pfizer Inc Auditor Perspective John C. McKenney, President & CEO SEC Associates, Inc Beat E. Widler, PhD, Global Head of Clinical Quality Assurance F. Hoffmann-La Roche

33 Emeralds of Experience
Session Chair: Mary Kuskin, RPh Pharmalink Consulting 33

34 Avoiding Accidents: Clinical Trial Disclosure Lessons Learned
Opportunity to share experience 15 minute presentation at the podium Practical examples to help others navigate the clinical trial disclosure field Topics include those presented at the workshop 34

35 Topics Clinical Trial Disclosure Law How to follow the road map
Process for posting after trial completion Registration and the Publication Plan Developing a company process Preparing for audit of public disclosure process 35

36 Guideline for Abstract Submission
All entries must be submitted online Deadline for submission is Sept 17, 2007 36

37 Questions and Answers

Download ppt "Clinical Trial Disclosure: Learning the Landscape and Reading the Roadmap DIA November 13-14, 2007 Hyatt Regency Bonaventure, Weston, Florida."

Similar presentations

Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.

Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
Disclosure I, Peter T. Katzmarzyk, PhD, FACSM, have no relationships with commercial interests to disclose. A commercial interest is any entity producing,

Disclosure I, Peter T. Katzmarzyk, PhD, FACSM, have no relationships with commercial interests to disclose. A commercial interest is any entity producing,
A service of the U.S. National Institutes of Health Module 1: Clinical Trials and Requirements for Registration and Results Reporting.

A service of the U.S. National Institutes of Health Module 1: Clinical Trials and Requirements for Registration and Results Reporting.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.

GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
MONITORING THE VALUE OF TRIAL REGISTER INFORMATION Thomson Pharmaceutical Services LAWRENCE LIBERTI MS, RPh, RAC JULY 16, 2008.

MONITORING THE VALUE OF TRIAL REGISTER INFORMATION Thomson Pharmaceutical Services LAWRENCE LIBERTI MS, RPh, RAC JULY 16, 2008.
The Registration of Clinical Trials Deborah A. Zarin, M.D. Director, ClinicalTrials.gov May 2007.

The Registration of Clinical Trials Deborah A. Zarin, M.D. Director, ClinicalTrials.gov May 2007.
11 February 2008NLM BOR WG on Clinical Trials1 Clinical Trials Registration and Results Reporting: Legislative Requirements Jerry Sheehan Assistant Director.

11 February 2008NLM BOR WG on Clinical Trials1 Clinical Trials Registration and Results Reporting: Legislative Requirements Jerry Sheehan Assistant Director.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.

Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Compliance Issues for Medical Research at Healthcare Systems Jerry Castellano, Pharm.D., CIP Corporate Director Institutional Review Board Christiana Care.

Compliance Issues for Medical Research at Healthcare Systems Jerry Castellano, Pharm.D., CIP Corporate Director Institutional Review Board Christiana Care.
ClinicalTrials.gov Tutorial Chicago Urban Health Outreach Project ClinicalTrials.gov Tutorial Use the buttons below to navigate. Start by clicking the.

ClinicalTrials.gov Tutorial Chicago Urban Health Outreach Project ClinicalTrials.gov Tutorial Use the buttons below to navigate. Start by clicking the.
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
International Congress and Convention Association International Association Overview Ross Robinson 44 th ICCA Congress & Exhibition, Monday, November 7.

International Congress and Convention Association International Association Overview Ross Robinson 44 th ICCA Congress & Exhibition, Monday, November 7.
After The Inspection When and How to Meet With FDA Presented by: Michael Santalucia Vice President Global Regulatory Affairs – Vision Care Medical Device.

After The Inspection When and How to Meet With FDA Presented by: Michael Santalucia Vice President Global Regulatory Affairs – Vision Care Medical Device.
Specialty Practice Pathologist Patient cap.org v. # Advocacy Workshop for Engaged Pathologists Mike Giuliani, Senior Director, Legislation and Political.

Specialty Practice Pathologist Patient cap.org v. # Advocacy Workshop for Engaged Pathologists Mike Giuliani, Senior Director, Legislation and Political.
CRIX: toward a secure, standards-based, clinical research information exchange.

CRIX: toward a secure, standards-based, clinical research information exchange.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.

+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
EFPIA and IFPMA Code Compliance Strategies Richard BERGSTRÖM Chair, EFPIA Code Steering Committee Chair, IFPMA Code Compliance Network Presentation at.

EFPIA and IFPMA Code Compliance Strategies Richard BERGSTRÖM Chair, EFPIA Code Steering Committee Chair, IFPMA Code Compliance Network Presentation at.
Agenda for Session Compliance in Clinical Research

Agenda for Session Compliance in Clinical Research
Ethical Issues in the Publication of Clinical Trial Information The International Pharmaceutical Compliance Summit on Medical Affairs, Clinical Trials,

Ethical Issues in the Publication of Clinical Trial Information The International Pharmaceutical Compliance Summit on Medical Affairs, Clinical Trials,
Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.

Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.

Similar presentations

Ads by Google